共 50 条
- [1] A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 434 - 434Kim, MisoMcDermott, Raymond S.Williamson, Stephen K.Cho, Byoung ChulDowlati, AfshinLakhani, Nehal J.Malhotra, JyotiKaczmar, John M.Papadopoulos, Kyriakos P.Safran, HowardAljumaily, RaidMani, JayakumarFang, FangChen, ShuquanSalvati, MarkLowy, IsraelFury, Matthew G.Lewis, Karl
- [2] A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCCJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Cho, Byoung ChulHamid, OmidZhu, XinhuaKeam, BhumsukKaczmar, John M.Williamson, Stephen K.Birnbaum, Ariel E.Dowlati, AfshinDy, Grace K.Hager, Steven JeffreyLynce, FilipaMcDermott, Raymond S.Sarker, DebashisWeise, Amy M.Yap, Timothy A.Yilmaz, EmrullahFang, FangMani, JayakumarKroog, Glenn ScottPapadopoulos, Kyriakos P.
- [3] A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysisJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Mehmi, InderjitLewis, Karl D.Weise, Amy M.McKean, MeredithPapadopoulos, Kyriakos P.Crown, JohnThomas, Sajeve SamuelGirda, EugeniaKaczmar, John M.Kim, Kevin B.Lakhani, Nehal J.Yushak, Melinda LynneHamid, OmidMani, JayakumarFang, FangLowy, IsraelGullo, Giuseppe
- [4] Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Hamid, OmidLewis, Karl D.Weise, Amym.McKean, MeredithPapadopoulos, Kyriakos P.Crown, JohnThomas, Sajeve SamuelGirda, EugeniaKaczmar, John M.Kim, Kevin B.Lakhani, NehalYushak, Melinda LynneMani, JayakumarFang, FangBrennan, LauraJankovic, VladimirPaccaly, Anne JoseeMasinde, SheilaLowy, IsraelGullo, Giuseppe
- [5] A phase 3 trial of fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanomaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Baramidze, AnaGogishvili, MirandaMakharadze, TamtaZhvania, MariamVacharadze, KhatunaCrown, JohnMelkadze, TamarHamid, OmidLong, Georgina V.Robert, CarolineSznol, MarioMartinez-Said, HectorMani, JayakumarChaudhry, UsmanSalvati, MarkLowy, IsraelFury, Matthew G.Gullo, Giuseppe
- [6] A phase 3 trial of fixed dose combinations of fianlimab (anti-LAG-3) + cemiplimab (anti-PD-1) versus relatlimab plus nivolumab in patients with unresectable or metastatic melanomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Khushalani, Nikhil I.Mani, JayakumarBooth, JocelynZhang, ZoeSalvati, MarkLowy, IsraelFury, Matthew G.Lewis, KarlManvelian, GarenTawbi, Hussein A.
- [7] A phase 3 trial comparing fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Panella, Timothy J.Thomas, Sajeve SamuelMcKean, MeredithMargolin, Kim AllysonWeight, Ryan MichaelMani, JayakumarPatel, ShraddhaDesai, PriyaSalvati, MarkLowy, IsraelFury, Matthew G.Gullo, Giuseppe
- [8] Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Hamid, OmidWang, DingKim, Tae MinKim, Sang-WeLakhani, Nehal J.Johnson, Melissa LynneGroisberg, RomanPapadopoulos, Kyriakos P.Kaczmar, John M.Middleton, Mark R.Spira, Alexander I.Williamson, Stephen K.Rabinowits, GuilhermeGutierrez, RodolfoMcKean, MeredithChen, ShuquanCassidy, JamesMani, JayakumarSims, Tasha NicholleKroog, Glenn
- [9] A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesONCOIMMUNOLOGY, 2024, 13 (01):Lin, Chia-ChiGarralda, ElenaSchoeffski, PatrickHong, David S.Siu, Lillian L.Martin, MiguelMaur, MichelaHui, RinaSoo, Ross A.Chiu, JoanneZhang, TianMa, BrigetteKyi, ChrisannTan, Daniel S. W.Cassier, Philippe A.Sarantopoulos, JohnWeickhardt, AndrewCarvajal, Richard D.Spratlin, JenniferEsaki, TaitoRolland, FredericAkerley, WallaceDeschler-Baier, BarbaraRispoli, LawrenceSamant, Tanay S.Chowdhury, Niladri RoyGusenleitner, DanielKwak, Eunice L.Askoxylakis, VasileiosDe Braud, Filippo
- [10] CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumoursBJC Reports, 3 (1):J. Randolph HechtJean-Marie MichotDavid BajorAmita PatnaikKi Y. ChungJudy WangGerald FalchookJames M. ClearyRichard KimAnuradha KrishnamurthyOmkar MaratheHagop YoussoufianCatherine EllisAngela WaszakSrimoyee GhoshHailei ZhangKaitlin YablonskiShruti D. ShahIvan Diaz-PadillaSusanna Ulahannan